> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts Liquidia’s NDA Resubmission for Yutrepia
- URL: https://www.fdaweb.com/fda-accepts-liquidias-nda-resubmission-for-yutrepia/
- Published: 2025-03-28T12:00:00.000Z
- Updated: 2026-09-14T14:56:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158916

FDA has accepted for review a Liquidia NDA resubmission for Yutrepia (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The agency confirmed that the resubmission was a complete Class 1 response to an 8/2024 action letter, which granted the drug a tentative approval for both PAH and PH-ILD. The agency has set a user fee review action target date of 5/24.

Liquidia says its inhaled dry powder formulation of treprostinil is designed using the company’s PRINT technology, which is intended to enhance deep-lung delivery using a palm-sized dry powder inhaler.